J. D. Smith's most recent trade in Sinclair Inc - Ordinary Shares - Class A was a trade of 629,700 Class B Common Stock done . Disclosure was reported to the exchange on March 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President/Secretary, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 06 Mar 2026 | 629,700 | 5,922,786 | - | - | Class B Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President/Secretary, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2026 | 629,700 | 629,700 | - | - | Class B Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President/Secretary, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Mar 2026 | 629,700 | 5,293,086 | - | - | Class B Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President/Secretary, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Mar 2026 | 629,700 | 5,293,086 | - | - | Class B Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President/Secretary, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 05 Mar 2026 | 629,700 | 5,922,786 | - | - | Class B Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President/Secretary, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 629,700 | 629,700 | - | - | Class B Common Stock | |
| Equifax | David John Smith | EVP, Pres USIS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 12,979 | 12,979 (0%) | 0% | 0 | Common Stock | |
| Equifax | David John Smith | EVP, Pres USIS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 9,979 | 22,958 (0%) | 0% | 0 | Common Stock | |
| Forward Air Corp | Douglas James Smith | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 5,850 | 13,810 (0%) | 0% | 0 | Common Stock | |
| Forward Air Corp | Douglas James Smith | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.78 per share. | 19 Feb 2026 | 516 | 13,294 (0%) | 0% | 27.8 | 14,334 | Common Stock |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 32,609 | 32,609 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 6,667 | 49,972 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 6,667 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 5,500 | 55,472 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 5,500 | 5,500 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 3,333 | 58,805 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 31 Jan 2026 | 3,217 | 55,588 (0%) | 0% | 19.7 | 63,343 | Ordinary Shares |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 31 Jan 2026 | 2,654 | 52,934 (0%) | 0% | 19.7 | 52,257 | Ordinary Shares |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 31 Jan 2026 | 1,608 | 51,326 (0%) | 0% | 19.7 | 31,662 | Ordinary Shares |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Grant, award, or other acquisition of securities at price $ 226.41 per share. | 29 Jan 2026 | 12,208 | 18,232 (0%) | 0% | 226.4 | 2,764,013 | Common Stock |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 226.41 per share. | 29 Jan 2026 | 4,166 | 14,066 (0%) | 0% | 226.4 | 943,224 | Common Stock |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Sale of securities on an exchange or to another person at price $ 219.59 per share. | 29 Jan 2026 | 690 | 13,376 (0%) | 0% | 219.6 | 151,514 | Common Stock |
| Evolent Health Inc (Class A) | Jill D. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 23,137 | 23,137 (0%) | 0% | 0 | Class A Common Stock | |
| Flowers Foods Inc | Joanne D. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 9,191 | 9,191 | - | - | Deferred Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President/Secretary, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 30 Dec 2025 | 13,600 | 5,293,086 | - | - | Class B Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President/Secretary, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Dec 2025 | 13,600 | 185 (0%) | 0% | 0 | Class A Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President/Secretary, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 30 Dec 2025 | 13,600 | 13,785 (0%) | 0% | 0 | Class A Common Stock | |
| Forward Air Corp | Douglas James Smith | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.47 per share. | 12 Dec 2025 | 243 | 7,960 (0%) | 0% | 25.5 | 6,189 | Common Stock |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2025 | 3,333 | 44,825 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2025 | 3,333 | 3,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 19.11 per share. | 07 Sep 2025 | 1,520 | 43,305 (0%) | 0% | 19.1 | 29,047 | Ordinary Shares |
| GMS Inc | J. David Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2025 | 1,350 | 33,857 (0%) | 0% | 0 | Common Stock | |
| GMS Inc | J. David Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2025 | 1,350 | 0 | - | - | Restricted Stock Units | |
| GMS Inc | J. David Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 1,141 | 1,141 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2025 | 16,500 | 49,014 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 19.14 per share. | 28 Jul 2025 | 7,522 | 41,492 (0%) | 0% | 19.1 | 143,971 | Ordinary Shares |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Vice President, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 17 Jun 2025 | 41,050 | 40,050 | - | - | Class B Common Stock | |
| Flowers Foods Inc | Joanne D. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 9,350 | 9,350 | - | - | Deferred Stock | |
| Bluelinx Hldgs Inc | J. David Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2025 | 2,074 | 2,074 | - | - | Restricted Stock Units | |
| Bluelinx Hldgs Inc | J. David Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 1,340 | 14,443 (0%) | 0% | - | Common Stock | |
| Bluelinx Hldgs Inc | J. David Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2025 | 1,340 | 0 | - | - | Restricted Stock Units | |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 231.37 per share. | 01 Mar 2025 | 62 | 6,067 (0%) | 0% | 231.4 | 14,345 | Common Stock |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Sale of securities on an exchange or to another person at price $ 234.81 per share. | 01 Mar 2025 | 43 | 6,024 (0%) | 0% | 234.8 | 10,097 | Common Stock |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 8,430 | 8,430 | - | - | Stock Option (Right to Buy) | |
| Forward Air Corp | Douglas James Smith | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 5,218 | 8,203 (0%) | 0% | 0 | Common Stock | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 6,667 | 33,135 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 6,667 | 6,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 5,500 | 35,281 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 5,500 | 11,000 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 3,354 | 29,781 (0%) | 0% | 11.1 | 37,364 | Ordinary Shares |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 2,767 | 32,514 (0%) | 0% | 11.1 | 30,824 | Ordinary Shares |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,500 | 27,726 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,500 | 0 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 11.14 per share. | 31 Jan 2025 | 1,258 | 26,468 (0%) | 0% | 11.1 | 14,014 | Ordinary Shares |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Grant, award, or other acquisition of securities at price $ 218.72 per share. | 30 Jan 2025 | 1,266 | 6,652 (0%) | 0% | 218.7 | 276,905 | Common Stock |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 218.72 per share. | 30 Jan 2025 | 332 | 6,320 (0%) | 0% | 218.7 | 72,616 | Common Stock |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Sale of securities on an exchange or to another person at price $ 220.22 per share. | 30 Jan 2025 | 191 | 6,129 (0%) | 0% | 220.2 | 42,062 | Common Stock |
| Flowers Foods Inc | Joanne D. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2024 | 4,866 | 4,866 | - | - | Deferred Stock | |
| Flowers Foods Inc | Joanne D. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 4,442 | 0 | - | - | Deferred Stock | |
| Flowers Foods Inc | Joanne D. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 4,442 | 9,102 (0%) | 0% | 0 | Common Stock | |
| R1 RCM Inc | Jill D. Smith | Director | Sale or transfer of securities back to the company at price $ 14.30 per share. | 19 Nov 2024 | 62,453 | 0 (0%) | 0% | 14.3 | 893,078 | Common Stock |
| R1 RCM Inc | Jill D. Smith | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Nov 2024 | 15,407 | 0 | - | - | Stock Option (right to buy) | |
| Delta Air Lines | Joanne D. Smith | EVP & Chief People Officer | 07 Nov 2024 | 19,660 | 85,123 (0%) | 0% | 64.7 | 1,272,002 | Common Stock | |
| Delta Air Lines | Joanne D. Smith | EVP & Chief People Officer | 07 Nov 2024 | 4,207 | 104,783 (0%) | 0% | 60.7 | 255,390 | Common Stock | |
| Delta Air Lines | Joanne D. Smith | EVP & Chief People Officer | 11 Oct 2024 | 3,431 | 108,990 (0%) | 0% | 50.5 | 173,132 | Common Stock | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 3,333 | 6,667 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2024 | 3,333 | 26,747 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Drew Smith | General Counsel | Sale of securities on an exchange or to another person at price $ 13.08 per share. | 09 Sep 2024 | 1,521 | 25,226 (0%) | 0% | 13.1 | 19,895 | Ordinary Shares |
| GMS Inc | J. David Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 1,672 | 0 | - | - | Restricted Stock Units | |
| GMS Inc | J. David Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 1,672 | 32,507 (0%) | 0% | 0 | Common Stock | |
| GMS Inc | J. David Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 1,350 | 1,350 | - | - | Restricted Stock Units | |
| R1 RCM Inc | Jill D. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 15,651 | 55,863 (0%) | 0% | 0 | Common Stock | |
| R1 RCM Inc | Jill D. Smith | Director | Grant, award, or other acquisition of securities at price $ 12.14 per share. | 23 May 2024 | 6,590 | 62,453 (0%) | 0% | 12.1 | 80,003 | Common Stock |
| Flowers Foods Inc | Joanne D. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 6,570 | 6,570 | - | - | Deferred Stock | |
| Flowers Foods Inc | Joanne D. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 4,660 | 4,660 (0%) | 0% | 0 | Common Stock | |
| Flowers Foods Inc | Joanne D. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 4,660 | 0 | - | - | Deferred Stock | |
| Bluelinx Hldgs Inc | J. David Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 1,561 | 13,103 (0%) | 0% | - | Common Stock | |
| Bluelinx Hldgs Inc | J. David Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 1,561 | 0 | - | - | Restricted Stock Units | |
| Bluelinx Hldgs Inc | J. David Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 1,340 | 1,340 | - | - | Restricted Stock Units | |
| Delta Air Lines | Joanne D. Smith | EVP & Chief People Officer | 08 May 2024 | 4,846 | 112,421 (0%) | 0% | 52.3 | 253,422 | Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Secretary, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2024 | 1,094,900 | 5,306,686 | - | - | Class B Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Secretary, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 03 Apr 2024 | 1,094,900 | 6,401,586 | - | - | Class B Common Stock | |
| Sinclair Inc (Class A) | J. Duncan Smith | Director, Secretary, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Apr 2024 | 1,094,900 | 1,094,900 | - | - | Class B Common Stock | |
| Waste Management | Donald J. Smith | Sr. VP - Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 9,302 | 9,302 | - | - | Stock Option (Right to Buy) | |
| Glimpse Grp Inc | David J. Smith | Director, Chief Creative Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 29 Feb 2024 | 64,349 | 0 | - | - | Stock Option (Right to Purchase) | |
| Glimpse Grp Inc | David J. Smith | Director, Chief Creative Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 51,480 | 51,480 | - | - | Stock Option (Right to Purchase) | |
| Delta Air Lines | Smith D. Joanne | EVP & Chief People Officer | 27 Feb 2024 | 4,876 | 117,267 (0%) | 0% | 42.0 | 204,904 | Common Stock | |
| Waste Management | J. Smith Donald | Sr. VP - Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 207.76 per share. | 23 Feb 2024 | 80 | 5,442 (0%) | 0% | 207.8 | 16,621 | Common Stock |
| Waste Management | J. Smith Donald | Sr. VP - Operations | Sale of securities on an exchange or to another person at price $ 207.79 per share. | 23 Feb 2024 | 56 | 5,386 (0%) | 0% | 207.8 | 11,636 | Common Stock |
| Waste Management | J. Smith Donald | Sr. VP - Operations | Grant, award, or other acquisition of securities at price $ 196.85 per share. | 13 Feb 2024 | 2,156 | 6,392 (0%) | 0% | 196.8 | 424,398 | Common Stock |
| Waste Management | J. Donald Smith | Sr. VP - Operations | Payment of exercise price or tax liability using portion of securities received from the company at price $ 196.84 per share. | 13 Feb 2024 | 541 | 5,851 (0%) | 0% | 196.8 | 106,493 | Common Stock |
| Waste Management | Donald Smith J. | Sr. VP - Operations | Sale of securities on an exchange or to another person at price $ 198.56 per share. | 13 Feb 2024 | 329 | 5,522 (0%) | 0% | 198.6 | 65,325 | Common Stock |
| Delta Air Lines | Joanne Smith D. | EVP & Chief People Officer | 07 Feb 2024 | 29,020 | 122,143 (0%) | 0% | - | Common Stock | ||
| Delta Air Lines | Smith D. Joanne | EVP & Chief People Officer | 01 Feb 2024 | 2,239 | 93,123 (0%) | 0% | 39.8 | 89,023 | Common Stock | |
| UroGen Pharma Ltd | Smith Drew Jason | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 16,500 | 16,500 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Smith Drew Jason | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 6,666 | 26,742 (0%) | 0% | - | Ordinary Shares | |
| UroGen Pharma Ltd | Jason Smith Drew | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 6,666 | 13,334 | - | - | Restricted Stock Units | |
| UroGen Pharma Ltd | Smith Drew Jason | General Counsel | Sale of securities on an exchange or to another person at price $ 15.74 per share. | 31 Jan 2024 | 3,328 | 23,414 (0%) | 0% | 15.7 | 52,383 | Ordinary Shares |
| UroGen Pharma Ltd | Smith Drew Jason | General Counsel | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 31 Jan 2024 | 3,328 | 23,414 (0%) | 0% | 15.8 | 52,516 | Ordinary Shares |